Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Single Center Pilot Study to Study The Effects of Metreleptin Administration in Patients With Type 1 Diabetes Mellitus ( T1DM ).

Next Previous
Search
Trial Profile

Open Label Single Center Pilot Study to Study The Effects of Metreleptin Administration in Patients With Type 1 Diabetes Mellitus ( T1DM ).

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metreleptin (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use

Most Recent Events

  • 02 May 2016 Primary endpoint of safety and tolerability of leptin removed and time frame for endpoint-Change in HgbA1c reduced from 5 months to 3 months. Trial focus changed.
  • 23 Jun 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
  • 20 Jun 2013 Planned end date changed from 1 Feb 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top